HER2-HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic targetReportar como inadecuado




HER2-HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Cancer and Metastasis Reviews

, Volume 36, Issue 1, pp 141–157

First Online: 15 December 2016DOI: 10.1007-s10555-016-9645-x

Cite this article as: Galdy, S., Lamarca, A., McNamara, M.G. et al. Cancer Metastasis Rev 2017 36: 141. doi:10.1007-s10555-016-9645-x

Abstract

Human epidermal growth factor receptor 2 HER2 overexpression and amplification have been reported as predictive markers for HER2-targeted therapy in breast and gastric cancer, whereas human epidermal growth factor receptor 3 HER3 is emerging as a potential resistance factor. The aim of this study was to perform a systematic review and meta-analysis of the HER2 and HER3 overexpression and amplification in biliary tract cancers BTCs. An electronic search of MEDLINE, American Society of Clinical Oncology ASCO, European Society of Medical Oncology Congress ESMO, and American Association for Cancer Research AACR was performed to identify studies reporting HER2 and-or HER3 membrane protein expression by immunohistochemistry IHC and-or gene amplification by in situ hybridization ISH in BTCs. Studies were classified as -high quality- HQ if IHC overexpression was defined as presence of moderate-strong staining or -low quality- LQ where -any- expression was considered positive. Of 440 studies screened, 40 met the inclusion criteria. Globally, HER2 expression rate was 26.5 % 95 % CI 18.9–34.1 %. When HQ studies were analyzed n = 27 studies, extrahepatic BTCs showed a higher HER2 overexpression rate compared to intrahepatic cholangiocarcinoma: 19.9 % 95 % CI 12.8–27.1 % vs. 4.8 % 95 % CI 0–14.5 %, respectively, p value 0.0049. HER2 amplification rate was higher in patients selected by HER2 overexpression compared to -unselected- patients: 57.6 % 95 % CI 16.2–99 % vs. 17.9 % 95 % CI 0.1–35.4 %, respectively, p value 0.0072. HER3 overexpression 4-4 HQ studies and amplification rates were 27.9 % 95 % CI 9.7–46.1 % and 26.5 % one study, respectively. Up to 20 % of extrahepatic BTCs appear to be HER2 overexpressed; of these, close to 60 % appear to be HER2 amplified, while HER3 is overexpressed or amplified in about 25 % of patients. Clinical relevance for targeted therapy should be tested in prospective clinical trials.

KeywordsBiliary tract cancer Cholangiocarcinoma HER2 pathway HER3 pathway Systematic review Meta-analysis  Download fulltext PDF



Autor: Salvatore Galdy - Angela Lamarca - Mairéad G. McNamara - Richard A. Hubner - Chiara A. Cella - Nicola Fazio - Juan W. 

Fuente: https://link.springer.com/







Documentos relacionados